The story of Sildenafil offers a complicated case study for investors eyeing the pharmaceutical sector. While initial sales were remarkable, recent patent expiration and the emergence of cheaper versions have https://heidiqlgw015019.activosblog.com/39629343/the-blue-pill-and-big-pharma-a-dangerous-bet